9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 77 of the 81 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although SGLT2 inhibitor use was not incorporated into American Diabetes Association guidelines until 2019,48”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [48]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (40).”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Research works printed but not linked: 6
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lexicon Pharmaceuticals . FDA to review ZynquistaTM (sotagliflozin) as potential treatment for type 1 diabetes [Internet], 2018. Available from http://www.lexpharma.com/media-center/news/673-fda-to-review-zynquista-sotagliflozin-as-potential-treatment-for-type-1-diabetes. Accessed 30 September 2018
- Institute for Clinical and Economic Review . Controversies in the management of patients with type 2 diabetes [Internet], December 2014. Available from https://icer-review.org/wp-content/uploads/2015/03/CEPAC-T2D-Final-Report-December-22.pdf. Accessed 9 November 2018
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
- Lipska, 2017, Human insulin for type 2 diabetes: an effective, less-expensive option, 23
Cited by
Items 101–200 of 773
Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function
Deng, M., Su, D., Xu, S., Little, P. J., Feng, X., Tang, L., & Shen, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00635 · Cited by 64
Acute Kidney Injury Associated With Semaglutide
Leehey, D. J., Rahman, M. A., Borys, E., Picken, M. M., & Clise, C. E. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2020.10.008 · Cited by 62
Adiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimer’s Disease
Kim, J. Y., Barua, S., Jeong, Y. J., & Lee, J. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176419 · Cited by 64
Chiba, Y., Sugiyama, Y., Nishi, N., Nonaka, W., Murakami, R., & Ueno, M. (2020) · Neuropathology · doi:10.1111/neup.12665 · Cited by 59
Hankosky, E. R., Schapiro, D., Gunn, K. B., Lubelczyk, E. B., Mitroi, J., & Nelson, D. R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01399-0 · Cited by 59
Builes-Montaño, C. E., Ortiz-Cano, N. A., Rincón, A. R., & Rojas-Henao, N. A. (2022) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.13017 · Cited by 67
Arrese, M. A., Francisco Barrera, M., Triantafilo, N., & Arab, J. P. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1649981 · Cited by 58
Zhou, X., Shrestha, S. S., Shao, H., & Zhang, P. (2020) · Diabetes Care · doi:10.2337/dc19-2273 · Cited by 57
Blonde, L., Belousova, L., Fainberg, U., Garcia‐Hernandez, P. A., Jain, S. M., Kaltoft, M. S., Mosenzon, O., Nafach, J., Palle, M. S., & Rea, R. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13978 · Cited by 54
Butler, J., Handelsman, Y., Bakris, G. L., & Verma, S. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1708 · Cited by 57
Giagulli, V. A., Castellana, M., Carbone, M. D., Pelusi, C., Ramunni, M. I., Pergola, G. D., Guastamacchia, E., & Triggiani, V. (2020) · Andrology · doi:10.1111/andr.12754 · Cited by 54
Darakjian, L., Deodhar, M., Turgeon, J., & Michaud, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094967 · Cited by 53
Dulaglutide: A Review in Type 2 Diabetes
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01260-9 · Cited by 56
Management of diabetes complications in youth
Graves, L. E., & Donaghue, K. C. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819863226 · Cited by 60
CHILTON, R. J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13854 · Cited by 54
McCoy, R. G., Lipska, K. J., Van Houten, H. K., & Shah, N. D. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001007 · Cited by 51
Rhee, J. J., Jardine, M., Chertow, G. M., & Mahaffey, K. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13987 · Cited by 55
Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review
Mohottige, D., Manley, H. J., & Hall, R. K. (2021) · Kidney360 · doi:10.34067/kid.0001942021 · Cited by 51
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 69
Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients
Kataria, Y., Ellervik, C., & Mandrup-Poulsen, T. R. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00743-6 · Cited by 56
Metformin lactic acidosis: Should we still be afraid?
Salvatore, T., Pafundi, P. C., Marfella, R., Sardu, C., Rinaldi, L., Monaco, L., Ricozzi, C., Imbriani, S., Nevola, R., Adinolfi, L. E., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107879 · Cited by 52
Duggan, E. W., & Chen, Y. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1277-4 · Cited by 51
Chew, N., Ng, C. H., Muthiah, M. D., & Sanyal, A. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01027-5 · Cited by 52
Katz, D. H., & Gavin, M. C. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201908060 · Cited by 55
Christensen, A. S., Hædersdal, S., Støy, J., Storgaard, H., Kampmann, U., Forman, J. L., Seghieri, M., Holst, J. J., Hansen, T., Knop, F. K., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0408 · Cited by 48
Yang, C., Yang, C., Ou, H., & Kuo, S. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01053-0 · Cited by 51
Chadha, M. D., Das, A. K., Deb, P., Gangopadhyay, K. K., Joshi, S., Kesavadev, J., KOVIL, R. R., Kumar, S., Misra, A., & Mohan, V. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01219-x · Cited by 60
Hadd, M. J., Bienhoff, S. E., Little, S. E., Geller, S., Ogne‐Stevenson, J., Dupree, T. J., & Scott‐Moncrieff, J. C. (2023) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16730 · Cited by 49
Alfayez, O. M., Almohammed, O. A., Alkhezi, O. S., Almutairi, A. R., & Al Yami, M. S. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01070-z · Cited by 41
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 57
Greiver, M., Havard, A., Bowles, J., Kalia, S., Chen, T., Aliarzadeh, B., Moineddin, R., Sherlock, J., Hinton, W., Sullivan, F., et al. (2020) · British Journal of General Practice · doi:10.3399/bjgp20x714089 · Cited by 46
C-Peptide as a Therapy for Type 1 Diabetes Mellitus
Washburn, R. L., Mueller, K., Kaur, G., Moreno, T., Moustaïd‐Moussa, N., Ramalingam, L., & Dufour, J. M. (2021) · Biomedicines · doi:10.3390/biomedicines9030270 · Cited by 55
Sameeh, M. Y., Khowdiary, M. M., Nassar, H. S., Abdelall, M. M., Alderhami, S. A., & Elhenawy, A. A. (2021) · Biomedicines · doi:10.3390/biomedicines10010024 · Cited by 47
Ogunyemi, B. T., Abdul-Hammed, M., Adedotun, I. O., Egunjobi, B. T., Badmos, S. T., Adegboyega, T. A., Aderogba, A., & Adeosun, G. G. (2025) · Discover Chemistry. · doi:10.1007/s44371-025-00130-1 · Cited by 44
Chen, S.-P., Lin, S., Chen, T., Ng, H. S., Yim, H.-S., Leong, M. K., & Weng, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112333 · Cited by 44
Kurani, S. S., Jeffery, M. M., Thorsteinsdottir, B., Hickson, L. J., Barreto, E. F., Haag, J. D., Giblon, R. E., Shah, N. D., & McCoy, R. G. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05557-8 · Cited by 43
Park, C. S., Choi, Y., Rhee, T., Lee, H. J., Lee, H., Park, J., Kim, Y.-J., Han, K., & Kim, H. (2022) · Diabetes Care · doi:10.2337/dc21-2299 · Cited by 44
Shilo, S., Godneva, A., Rachmiel, M., Korem, T., Kolobkov, D., Karady, T., Bar, N., Wolf, B. C., Glantz-Gashai, Y., Cohen, M., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1048 · Cited by 43
Wilson, J. B., Epstein, M., Lopez, B., Brown, A. K., Lutfy, K., & Friedman, T. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1224612 · Cited by 46
Yasuda, M., Iizuka, K., Kato, T., Liu, Y., Takao, K., Nonomura, K., Mizuno, M., & Yabe, D. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13137 · Cited by 43
Glucose metabolism in Cushing's syndrome
Sharma, A. R., & Vella, A. V. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000537 · Cited by 44
Li, J., He, K., Ge, J., Li, C., & Jing, Z. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108656 · Cited by 45
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 38
Shao, S., Lin, Y.-H., Chang, K., Chan, Y., Hung, M., Yang, Y. K., & Lai, E. C. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000742 · Cited by 40
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Zachou, M., Flevari, P., Ansari, N. N., Varytimiadis, C., Kalaitzakis, E., Kassi, E. N., & Ανδρουτσάκος, Θ. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03586-1 · Cited by 41
“Metformin improves glycemic control, without leading to weight gain or severe hypoglycemia [32, 33].”
BackgroundBenefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
Kaku, K., Kisanuki, K., Shibata, M., & Oohira, T. (2019) · Drug Safety · doi:10.1007/s40264-019-00857-8 · Cited by 42
Shigeoka, T., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Horikawa, T., Tanaka, T., Irie, S., Motonaga, R., Hamanoue, N., Tanabe, M., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13247 · Cited by 39
Shin, J.-I., Sang, Y., Chang, A. R., Dunning, S. C., Coresh, J., Inker, L. A., Selvin, E., Ballew, S. H., & Grams, M. E. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019101119 · Cited by 38
Gomes, A., Coelho, P. P. O. L., Soares, R. A., & Costa, R. (2021) · Cell and Tissue Research · doi:10.1007/s00441-021-03461-4 · Cited by 39
Morton, J. I., Marquina, C., Shaw, J. E., Liew, D., Polkinghorne, K. R., Ademi, Z., & Magliano, D. J. (2022) · Diabetologia · doi:10.1007/s00125-022-05832-0 · Cited by 39
Song, H., Fu, F., Chen, Y., Yang, R., Luo, Z., Shao, J., Qi, Y., Zhang, Q., Wang, J., Sun, H., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123489 · Cited by 39
Watada, H., Takami, A., Spranger, R., Amano, A., Hashimoto, Y., & Niemoeller, E. (2020) · Diabetes Care · doi:10.2337/dc19-2452 · Cited by 38
Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
Giugliano, D., Nicola, L. D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13743 · Cited by 37
Schwingshackl, L., Schwarzer, G., Rücker, G., & Meerpohl, J. J. (2019) · Advances in Nutrition · doi:10.1093/advances/nmz036 · Cited by 37
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
Ja’arah, D., Al Zoubi, M. S., Abdelhady, G., Rabi, F., & Tambuwala, M. M. (2021) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/11795514211051697 · Cited by 35
Pérez-Belmonte, L. M., Osuna-Sánchez, J., Millán-Gómez, M., López-Carmona, M. D., Gómez-Doblas, J. J., Cobos-Palacios, L., Sanz-Cánovas, J., Barbancho, M. A., Lara, J. P., Jiménez-Navarro, M., et al. (2019) · Annals of Medicine · doi:10.1080/07853890.2019.1613672 · Cited by 36
Kaneto, H., Takami, A., Spranger, R., Amano, A., Watanabe, D., & Niemoeller, E. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14005 · Cited by 36
Cardiometabolic Medicine: Development of a New Subspecialty
Saxon, D. R., Reiter–Brennan, C., Blaha, M. J., & Eckel, R. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa261 · Cited by 38
Wake, A. D. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i3.161 · Cited by 36
Matias, L. L. R., Costa, R. O., Passos, T. S., de Queiroz, J. L. C., Serquiz, A. C., Maciel, B. L. L., Santos, P. P. D. A., Camillo, C. D. S., Gonçalves, C., Amado, I. R., et al. (2019) · Nutrients · doi:10.3390/nu11112770 · Cited by 36
McGill, J. B., Peters, A., Buse, J. B., Steiner, S., Tran, T., Pompilio, F. M., & Kendall, D. M. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00958-8 · Cited by 35
Maiorino, M. I., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., & Esposito, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.06.009 · Cited by 36
Zhou, J., Wang, Q., Xiang, Z.-N., Tong, Q., Pan, J., Wan, L.-S., & Chen, J. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/4202563 · Cited by 35
Clinical potential of treatment with semaglutide in type 2 diabetes patients
Røder, M. E. (2019) · Drugs in Context · doi:10.7573/dic.212585 · Cited by 37
Effects of Dietary Red Raspberry Consumption on Pre-Diabetes and Type 2 Diabetes Mellitus Parameters
Derrick, S. A., Kristo, A. S., Reaves, S. K., & Sikalidis, A. K. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18179364 · Cited by 39
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 38
Mahboob, A., Senevirathne, D. K. L., Paul, P., Nabi, F., Khan, R. H., & Châari, A. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.038 · Cited by 39
Aroda, V. R., Capehorn, M., CHAYKIN, L. B., Frías, J. P., Lausvig, N. L., Macura, S., Lüdemann, J., Madsbad, S., Rosenstock, J., Tabak, Ö., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13896 · Cited by 36
“1,2 Clinically relevant reductions in HbA1c and BW were observed in all assessed background medication subgroups of the SUSTAIN 1-5 trials and considerable weight loss was observed with semaglutide 1.0 mg, even in patients on a background of stable basal insulin ± metformin.”
BackgroundInfluentialWang, T., Patel, S. M., Hickman, A., Liu, X., Jones, P. L., Gantz, I., & Koro, C. E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00771-8 · Cited by 34
Khunti, K., Hassanein, M. M., Lee, M., Mohan, V., & Amod, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00833-x · Cited by 38
Glucose, Fructose, and Urate Transporters in the Choroid Plexus Epithelium
Chiba, Y., Murakami, R., Matsumoto, K., Wakamatsu, K., Nonaka, W., Uemura, N., Yanase, K., Kamada, M., & Ueno, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197230 · Cited by 34
Sanogo, F., Xu, K., Cortessis, V. K., Weigensberg, M. J., & Watanabe, R. M. (2022) · Journal of Integrative and Complementary Medicine · doi:10.1089/jicm.2022.0586 · Cited by 34
“…practices, complementary medicine, type 2 diabetes, clinical practice, epidemiology Introduction D espite the availability of a range of therapies 1,2 to address the management of hyperglycemia, it is estimated that only 51% of patients with type 2 diabetes achieve the therapeutic target of…”
Huang, Y., Lou, X., Jiang, C., Ji, X., Tao, X., Sun, J., & Bao, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1044030 · Cited by 35
Barengolts, E. I., Green, S. J., Chlipala, G. E., Layden, B. T., Eisenberg, Y., Priyadarshini, M., & Dugas, L. R. (2019) · Microorganisms · doi:10.3390/microorganisms7090320 · Cited by 35
Management of type 2 diabetes: consensus of diabetes organizations
Quattrocchi, E. J., Goldberg, T., & Marzella, N. (2020) · Drugs in Context · doi:10.7573/dic.212607 · Cited by 36
Metformin May Contribute to Inter-individual Variability for Glycemic Responses to Exercise
Malin, S. K., & Stewart, N. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00519 · Cited by 34
Bonaventura, A., Carbone, S., Dixon, D. L., Abbate, A., & Montecucco, F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12890 · Cited by 36
Gæde, P., Johansen, P., Tikkanen, C. K., Pollock, R. F., Hunt, B., & Malkin, S. J. P. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0630-6 · Cited by 32
Ürgeová, A., Javorský, M., Klimčáková, L., Židzik, J., Salagovic, J., Hubacek, J. A., Doubravová, P., Gotthardová, I., Kvapil, M., Pelikánová, T., et al. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0147 · Cited by 32
Leohr, J. K., Dellva, M. A., Coutant, D. E., LaBell, E. S., Heise, T., Andersen, G., Zijlstra, E., Hermanski, L., Nosek, L., & Linnebjerg, H. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00901-2 · Cited by 32
Chen, T., Li, Y., Chen, S., Lin, Y., Sun, C., Chen, D., Mao, C., Michael Shengtao, W. U., Chang, C., Chu, P., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01169-3 · Cited by 32
Nørgaard, C. H., Starkopf, L., Gerds, T. A., Vestergaard, P., Bonde, A. N., Fosbøl, E. L., Køber, L., Wong, N. D., Torp-Pedersen, C. T., & Lee, C. J.-Y. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab053 · Cited by 32
Rea, F., Ciardullo, S., Savaré, L., Perseghin, G., & Corrao, G. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109035 · Cited by 33
Demoz, G. T., Wahdey, S., Kasahun, G. G., Hagazy, K., Kinfe, D. G., Atalay, H. T., Tadesse, D. B., & Niriayo, Y. L. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4423-9 · Cited by 32
Lin, S., Chang, C., Tsai, M., Cheng, H., Chen, J.-C., Leong, M. K., & Weng, C. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319875305 · Cited by 37
Lichtash, C. T., Fung, J., Ostoich, K. C., & Ramos, M. (2020) · BMJ Case Reports · doi:10.1136/bcr-2019-234223 · Cited by 36
Rong, X., Li, X., Gou, Q., Liu, K., & Chen, X. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120953625 · Cited by 32
Forst, T. M., Choudhary, P., Schneider, D., Linetzky, B., & Pozzilli, P. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3418 · Cited by 34
Rattelman, C. R., Ciemins, E. L., Stempniewicz, N., Mocarski, M., Ganguly, R., & Cuddeback, J. K. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00993-w · Cited by 31
Handelsman, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01054-w · Cited by 34
“…be guided by patient needs, including avoidance of adverse effects (e.g., hypoglycemia and body weight gain), cost considerations, or other needs [8], while the AACE/ACE guidelines recommend a hierarchy of use for add-on glucose-lowering therapy based on safety and effi-cacy and consideration of…”
BackgroundInfluentialHur, K. Y., Kim, M. K., Ko, S., Han, M., Lee, D. W., & Kwon, H. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0004 · Cited by 32
Sullivan, S. D., Nicholls, C. J., Gupta, R. A., Menon, A. A., Wu, J., Westerbacka, J., Bosnyák, Z., Frías, J. P., & Bailey, T. S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13793 · Cited by 30
Lingvay, I., Capehorn, M., Catarig, A., Johansen, P., Lawson, J., Sandberg, A., Shaw, R., & Paine, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa577 · Cited by 31
Do, J. Y., Kim, S. W., Park, J. W., Cho, K. H., & Kang, S. H. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.10.006 · Cited by 30
Hales, C. M., Gu, Q., Ogden, C. L., & Yanovski, S. Z. (2021) · Obesity · doi:10.1002/oby.23299 · Cited by 30
Butler, J., Packer, M., Greene, S. J., Fiuzat, M., Anker, S. D., Anstrom, K. J., Carson, P. E., Cooper, L. B., Fonarow, G. C., Hernandez, A. F., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042155 · Cited by 30
SGLT-2 inhibitors in diabetes: a focus on renoprotection
Gonzalez, D. E., Foresto, R. D., & Ribeiro, A. B. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.s1.17 · Cited by 38
Salas, J., Morley, J. E., Scherrer, J. F., Floyd, J. S., Farr, S. A., Zubatsky, M., Barthold, D., & Dublin, S. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5014 · Cited by 30
Kaku, K., Araki, E., Tanizawa, Y., Agner, B. F. R., Nishida, T., Ranthe, M. F., & Inagaki, N. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13856 · Cited by 32
Drug interactions with antimalarial medications in older travelers: a clinical guide
Lewis, J., Gregorian, T., Portillo, I., & Goad, J. A. (2019) · Journal of Travel Medicine · doi:10.1093/jtm/taz089 · Cited by 31
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S90-S102
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4212810717
- Cited by
- 739
- References
- 81
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 30 · 2023: 47 · 2022: 69 · 2021: 126 · 2020: 246 · 2019: 181
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Societies, Medical, United States, Practice Guidelines as Topic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.